Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study involving tenofovir disoproxil fumarate (TDF) will assess the extended
safety of TDF 300 mg per day among young women who are not HIV-infected.